Cardiogenic Shock Questions & Answers

1. [Guideline] van Diepen S, Katz JN, Albert NM, et al, for the American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement From the American Heart Association. Circulation. 2017 Oct 17. 136 (16):e232-68. [QxMD MEDLINE Link]. [Full Text].

2. Alonso DR, Scheidt S, Post M, Killip T. Pathophysiology of cardiogenic shock. Quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlations. Circulation. 1973 Sep. 48 (3):588-96. [QxMD MEDLINE Link].

3. Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008 Feb 5. 117(5):686-97. [QxMD MEDLINE Link].

4. Funaro S, La Torre G, Madonna M, et al, for the AMICI Investigators. Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study. Eur Heart J. 2009 Mar. 30 (5):566-75. [QxMD MEDLINE Link].

5. Forrester JS, Wyatt HL, Da Luz PL, Tyberg JV, Diamond GA, Swan HJ. Functional significance of regional ischemic contraction abnormalities. Circulation. 1976 Jul. 54 (1):64-70. [QxMD MEDLINE Link].

6. Beyersdorf F, Buckberg GD, Acar C, et al. Cardiogenic shock after acute coronary occlusion. Pathogenesis, early diagnosis, and treatment. Thorac Cardiovasc Surg. 1989 Feb. 37 (1):28-36. [QxMD MEDLINE Link].

7. Al-Reesi A, Al-Zadjali N, Perry J, et al. Do beta-blockers reduce short-term mortality following acute myocardial infarction? A systematic review and meta-analysis. CJEM. 2008 May. 10(3):215-23. [QxMD MEDLINE Link].

8. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 Nov 5. 366(9497):1622-32. [QxMD MEDLINE Link].

9. Kolte D, Khera S, Aronow WS, et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc. 2014 Jan 13. 3 (1):e000590. [QxMD MEDLINE Link].

10. Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med. 1999 Apr 15. 340(15):1162-8. [QxMD MEDLINE Link].

11. [Guideline] Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14. 37 (3):267-315. [QxMD MEDLINE Link]. [Full Text].

12. Graf T, Desch S, Eitel I, Thiele H. Acute myocardial infarction and cardiogenic shock: pharmacologic and mechanical hemodynamic support pathways. Coron Artery Dis. 2015 Sep. 26 (6):535-44. [QxMD MEDLINE Link].

13. Rab T, O'Neill W. Mechanical circulatory support for patients with cardiogenic shock. Trends Cardiovasc Med. 2018 Dec 5. [QxMD MEDLINE Link].

14. Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005 Jul 27. 294(4):448-54. [QxMD MEDLINE Link].

15. Fox KA, Steg PG, Eagle KA, Goodman SG, Anderson FA Jr, Granger CB, et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA. 2007 May 2. 297(17):1892-900. [QxMD MEDLINE Link].

16. Jeger RV, Radovanovic D, Hunziker PR, Pfisterer ME, Stauffer JC, Erne P, et al. Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med. 2008 Nov 4. 149(9):618-26. [QxMD MEDLINE Link].

17. [Guideline] Amsterdam EA, Wenger NK, Brindis RG, et al, for the ACC, AHA Task Force on Practice Guidelines, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23. 64 (24):e139-228. [QxMD MEDLINE Link]. [Full Text].

18. Kunadian V, Qiu W, Ludman P, et al, for the National Institute for Cardiovascular Outcomes Research. Outcomes in patients with cardiogenic shock following percutaneous coronary intervention in the contemporary era: an analysis from the BCIS database (British Cardiovascular Intervention Society). JACC Cardiovasc Interv. 2014 Dec. 7 (12):1374-85. [QxMD MEDLINE Link].

19. Hamon M, Agostini D, Le Page O, Riddell JW, Hamon M. Prognostic impact of right ventricular involvement in patients with acute myocardial infarction: meta-analysis. Crit Care Med. 2008 Jul. 36(7):2023-33. [QxMD MEDLINE Link].

20. Garan AR, Eckhardt C, Takeda K, et al. Predictors of survival and ability to wean from short-term mechanical circulatory support device following acute myocardial infarction complicated by cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2018 Dec. 7 (8):755-65. [QxMD MEDLINE Link].

21. Hasdai D, Califf RM, Thompson TD, Hochman JS, Ohman EM, Pfisterer M, et al. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol. 2000 Jan. 35(1):136-43. [QxMD MEDLINE Link].

22. Picard MH, Davidoff R, Sleeper LA, and the SHOCK Trial investigators. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation. 2003 Jan 21. 107 (2):279-84. [QxMD MEDLINE Link].

23. Jeger RV, Lowe AM, Buller CE, Pfisterer ME, Dzavik V, Webb JG, et al. Hemodynamic parameters are prognostically important in cardiogenic shock but similar following early revascularization or initial medical stabilization: a report from the SHOCK Trial. Chest. 2007 Dec. 132(6):1794-803. [QxMD MEDLINE Link].

24. Baliga RR. Management of cardiogenic shock: AHA scientific statement. Available at https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/10/06/11/36/contemporary-management-of-cardiogenic-shock. October 6, 2017; Accessed: August 5, 2019.

25. [Guideline] O'Gara PT, Kushner FG, Ascheim DD, et al, for the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Jan 29. 127 (4):e362-425. [QxMD MEDLINE Link]. [Full Text].

26. Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, et al. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001 Jan 10. 285(2):190-2. [QxMD MEDLINE Link].

27. Shin TG, Choi JH, Jo IJ, Sim MS, Song HG, Jeong YK, et al. Extracorporeal cardiopulmonary resuscitation in patients with inhospital cardiac arrest: A comparison with conventional cardiopulmonary resuscitation. Crit Care Med. 2011 Jan. 39(1):1-7. [QxMD MEDLINE Link].

28. Choi MS, Sung K, Cho YH. Clinical pearls of venoarterial extracorporeal membrane oxygenation for cardiogenic shock. Korean Circ J. 2019 Aug. 49 (8):657-77. [QxMD MEDLINE Link].

29. McGugan PL. The role of venoarterial extracorporeal membrane oxygenation in postcardiotomy cardiogenic shock. Crit Care Nurs Clin North Am. 2019 Sep. 31 (3):419-36. [QxMD MEDLINE Link].

30. De Backer D, Biston P, Devriendt J, et al, for the SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010 Mar 4. 362 (9):779-89. [QxMD MEDLINE Link].

31. Ellender TJ, Skinner JC. The use of vasopressors and inotropes in the emergency medical treatment of shock. Emerg Med Clin North Am. 2008 Aug. 26(3):759-86, ix. [QxMD MEDLINE Link].

32. Naples RM, Harris JW, Ghaemmaghami CA. Critical care aspects in the management of patients with acute coronary syndromes. Emerg Med Clin North Am. 2008 Aug. 26(3):685-702, viii. [QxMD MEDLINE Link].

33. Felker GM, Benza RL, Chandler AB, et al, for the OPTIME-CHF Investigators. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003 Mar 19. 41 (6):997-1003. [QxMD MEDLINE Link].

34. Gheorghiade M, Gattis WA, Klein L. OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalization. Eur J Heart Fail. 2003 Jan. 5 (1):9-12. [QxMD MEDLINE Link].

35. Fuhrmann JT, Schmeisser A, Schulze MR, Wunderlich C, Schoen SP, Rauwolf T, et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2008 Aug. 36(8):2257-66. [QxMD MEDLINE Link].

36. De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J. 2006 Aug. 27(16):1908-20. [QxMD MEDLINE Link].

37. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986 Feb 22. 1 (8478):397-402. [QxMD MEDLINE Link].

38. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet. 1987 Oct 17. 2 (8564):871-4. [QxMD MEDLINE Link].

39. Sanborn TA, Sleeper LA, Bates ER, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?. J Am Coll Cardiol. 2000 Sep. 36(3 Suppl A):1123-9. [QxMD MEDLINE Link].

40. Garatti A, Russo C, Lanfranconi M, Colombo T, Bruschi G, Trunfio S, et al. Mechanical circulatory support for cardiogenic shock complicating acute myocardial infarction: an experimental and clinical review. ASAIO J. 2007 May-Jun. 53(3):278-87. [QxMD MEDLINE Link].

41. Cheng JM, den Uil CA, Hoeks SE, van der Ent M, Jewbali LS, van Domburg RT, et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J. 2009 Sep. 30(17):2102-8. [QxMD MEDLINE Link].

42. Sjauw KD, Engstrom AE, Vis MM, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines?. Eur Heart J. 2009 Feb. 30 (4):459-68. [QxMD MEDLINE Link].

43. Ramanathan K, Farkouh ME, Cosmi JE, French JK, Harkness SM, Džavík V, et al. Rapid complete reversal of systemic hypoperfusion after intra-aortic balloon pump counterpulsation and survival in cardiogenic shock complicating an acute myocardial infarction. Am Heart J. 2011 Aug. 162(2):268-75. [QxMD MEDLINE Link]. [Full Text].

44. Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012 Oct 4. 367(14):1287-96. [QxMD MEDLINE Link].

45. Dudzinsk JE, Gnall E, Kowey PR. A review of percutaneous mechanical support devices and strategies. Rev Cardiovasc Med. 2018 Mar 30. 19 (1):21-6. [QxMD MEDLINE Link].

46. Fryer ML, Balsam LB. Mechanical circulatory support for cardiogenic shock in the critically ill. Chest. 2019 Jul 30. [QxMD MEDLINE Link].

47. Windecker S. Percutaneous left ventricular assist devices for treatment of patients with cardiogenic shock. Curr Opin Crit Care. 2007 Oct. 13(5):521-7. [QxMD MEDLINE Link].

48. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001 Nov 15. 345(20):1435-43. [QxMD MEDLINE Link].

49. Farrar DJ, Lawson JH, Litwak P, Cederwall G. Thoratec VAD system as a bridge to heart transplantation. J Heart Transplant. 1990 Jul-Aug. 9(4):415-22; discussion 422-3. [QxMD MEDLINE Link].

50. Damme L, Heatley J, Radovancevic B. Clinical results with the HeartMate LVAD: Worldwide Registry update. J Congestive Heart Failure Circ Support. 2001. 2:5-7(3).

51. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999 Aug 26. 341(9):625-34. [QxMD MEDLINE Link].

52. Antoniucci D, Valenti R, Migliorini A, Moschi G, Trapani M, Buonamici P, et al. Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol. 2002 Jun 1. 89(11):1248-52. [QxMD MEDLINE Link].

53. Hochman JS, Boland J, Sleeper LA, Porway M, Brinker J, Col J, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators. Circulation. 1995 Feb 1. 91(3):873-81. [QxMD MEDLINE Link].

54. Jeger RV, Harkness SM, Ramanathan K, et al, for the SHOCK Investigators. Emergency revascularization in patients with cardiogenic shock on admission: a report from the SHOCK trial and registry. Eur Heart J. 2006 Mar. 27 (6):664-70. [QxMD MEDLINE Link].

55. Hochman JS, Sleeper LA, Webb JG, et al, for the SHOCK Investigators. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA. 2006 Jun 7. 295 (21):2511-5. [QxMD MEDLINE Link].

56. [Guideline] Ponikowski P, Voors AA, Anker SD, et al, Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14. 37 (27):2129-200. [QxMD MEDLINE Link]. [Full Text].

57. [Guideline] Rihal CS, Naidu SS, Givertz MM, et al. 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care: Endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention. J Am Coll Cardiol. 2015 May 19. 65 (19):e7-e26. [QxMD MEDLINE Link]. [Full Text].

58. [Guideline] Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013 Feb. 32 (2):157-87. [QxMD MEDLINE Link]. [Full Text].

59. Slottosch I, Liakopoulos O, Kuhn E, Deppe AC, Scherner M, Madershahian N, et al. Outcomes after peripheral extracorporeal membrane oxygenation therapy for postcardiotomy cardiogenic shock: a single-center experience. J Surg Res. 2013 May. 181 (2):e47-55. [QxMD MEDLINE Link].

60. Anderson ML, Peterson ED, Peng SA, et al. Differences in the profile, treatment, and prognosis of patients with cardiogenic shock by myocardial infarction classification: A report from NCDR. Circ Cardiovasc Qual Outcomes. 2013 Nov. 6 (6):708-15. [QxMD MEDLINE Link].

61. Menon V, White H, LeJemtel T, et al. The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK?. J Am Coll Cardiol. 2000 Sep. 36 (3 suppl A):1071-6. [QxMD MEDLINE Link].

62. Koprivanac M, Kelava M, Soltesz E, et al. Advances in temporary mechanical support for treatment of cardiogenic shock. Expert Rev Med Devices. 2015 Nov. 12 (6):689-702. [QxMD MEDLINE Link].

63. Susen S, Rauch A, Van Belle E, Vincentelli A, Lenting PJ. Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis. J Thromb Haemost. 2015 Oct. 13 (10):1757-67. [QxMD MEDLINE Link].

64. Miller PE, Guha A, Khera R, et al. National trends in healthcare-associated infections for five common cardiovascular conditions. Am J Cardiol. 2019 Jul 16. [QxMD MEDLINE Link].

Xiushui (Mike) Ren, MD Cardiologist, The Permanente Medical Group; Associate Director of Research, Cardiovascular Diseases Fellowship, California Pacific Medical Center

Xiushui (Mike) Ren, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American Society of Echocardiography

Disclosure: Nothing to disclose.

Andrew Lenneman, MD Associate Professor of Medicine (Cardiovascular Disease, Scientist, Comprehensive Cardiovascular Center, University of Alabama School of Medicine

Disclosure: Nothing to disclose.

Henry H Ooi, MD, MRCPI Director, Advanced Heart Failure and Cardiac Transplant Program, Nashville Veterans Affairs Medical Center; Assistant Professor of Medicine, Vanderbilt University School of Medicine

Disclosure: Nothing to disclose.

Ethan S Brandler, MD, MPH Clinical Assistant Professor, Attending Physician, Departments of Emergency Medicine and Internal Medicine, University Hospital of Brooklyn, Kings County Hospital

Ethan S Brandler, MD, MPH is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

David FM Brown, MD Associate Professor, Division of Emergency Medicine, Harvard Medical School; Vice Chair, Department of Emergency Medicine, Massachusetts General Hospital

David FM Brown, MD is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Daniel J Dire, MD, FACEP, FAAP, FAAEM Clinical Professor, Department of Emergency Medicine, University of Texas Medical School at Houston; Clinical Professor, Department of Pediatrics, University of Texas Health Sciences Center San Antonio

Daniel J Dire, MD, FACEP, FAAP, FAAEM is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American Academy of Pediatrics, American College of Emergency Physicians, and Association of Military Surgeons of the US

Disclosure: Nothing to disclose.

Mark A Hostetler, MD, MPH Associate Professor of Pediatrics, University of Chicago; Chief, Section of Emergency Medicine, Department of Pediatrics, Medical Director of Pediatric Emergency Department, University of Chicago Children's Hospital

Disclosure: Nothing to disclose.

A Antoine Kazzi MD, Deputy Chief of Staff, American University of Beirut Medical Center; Associate Professor, Department of Emergency Medicine, American University of Beirut, Lebanon

A Antoine Kazzi is a member of the following medical societies: American Academy of Emergency Medicine

Disclosure: Nothing to disclose.

Russell F Kelly MD, Assistant Professor, Department of Internal Medicine, Rush Medical College; Chairman of Adult Cardiology and Director of the Fellowship Program, Cook County Hospital

Russell F Kelly is a member of the following medical societies: American College of Cardiology

Disclosure: Nothing to disclose.

Ronald J Oudiz, MD, FACP, FACC, FCCP Professor of Medicine, University of California, Los Angeles, David Geffen School of Medicine; Director, Liu Center for Pulmonary Hypertension, Division of Cardiology, LA Biomedical Research Institute at Harbor-UCLA Medical Center

Ronald J Oudiz, MD, FACP, FACC, FCCP is a member of the following medical societies: American College of Cardiology, American College of Chest Physicians, American College of Physicians, American Heart Association, and American Thoracic Society

Disclosure: Actelion Grant/research funds Clinical Trials + honoraria; Encysive Grant/research funds Clinical Trials + honoraria; Gilead Grant/research funds Clinical Trials + honoraria; Pfizer Grant/research funds Clinical Trials + honoraria; United Therapeutics Grant/research funds Clinical Trials + honoraria; Lilly Grant/research funds Clinical Trials + honoraria; LungRx Clinical Trials + honoraria; Bayer Grant/research funds Consulting

Sat Sharma, MD, FRCPC Professor and Head, Division of Pulmonary Medicine, Department of Internal Medicine, University of Manitoba; Site Director, Respiratory Medicine, St Boniface General Hospital

Sat Sharma, MD, FRCPC is a member of the following medical societies: American Academy of Sleep Medicine, American College of Chest Physicians, American College of Physicians-American Society of Internal Medicine, American Thoracic Society, Canadian Medical Association, Royal College of Physicians and Surgeons of Canada, Royal Society of Medicine, Society of Critical Care Medicine, and World Medical Association

Disclosure: Nothing to disclose.

Richard H Sinert, DO Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center

Richard H Sinert, DO is a member of the following medical societies: American College of Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

• Print this section
• Print the entire contents of
• Print the entire contents of article